Novo Nordisk

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares up $1.06, or 2.11%, near $51.62. Options volume running well above average with 56k c...

Novo Nordisk NVO received a boost after the European Commission (EC) approved once-daily oral version of Wegovy (semaglutide 25 mg) for the treatment of adults...

The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states. It follows a...

Novo Nordisk (NVO) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an ETF b...

Advertisement Share repurchase update gives investors fresh data point Novo Nordisk (NVO) has updated investors on its ongoing share repurchase programme, wit...

Novo Nordisk’s Wegovy pill is the market leader for new oral weight-loss drugs. George Frey / Bloomberg News The launch of weight-loss pills is the hottest bat...

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. R...

Novo Nordisk A/S (NYSE:NVO) on Saturday presented new phase 3 data supporting the long-term safety and efficacy of investigational hemophilia A treatment deneci...

Novo Nordisk (NVO) unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig subcut...

Novo Nordisk A/S (NVO), a global healthcare company best known for its diabetes and obesity treatments, reported new phase 3 data that could strengthen its posi...